These authors contributed equally to this work.
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors
Article first published online: 6 AUG 2012
© 2012 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 25, Issue 5, pages 569–572, September 2012
How to Cite
Anforth, R., Tembe, V., Blumetti, T. and Fernandez-Peñas, P. (2012), Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell & Melanoma Research, 25: 569–572. doi: 10.1111/j.1755-148X.2012.01031.x
- Issue published online: 28 AUG 2012
- Article first published online: 6 AUG 2012
- Accepted manuscript online: 23 JUN 2012 09:09AM EST
- PUBLICATION DATA Received 8 March 2012, revised and accepted for publication 19 June 2012, published online 23 June 2012
- BRAF inhibitors;
- squamous cell carcinoma;
- verrucal keratosis
B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival in patients with stage IV metastatic melanoma positive for the BRAF V600E mutation. However, the main drawback is the development of verrucal keratosis (hyperkeratotic papules with verruca-like characteristics with benign histological findings) and cutaneous squamous cell carcinomas (cuSCC). We have found upstream mutations in RAS as well as PIK3CA in both verrucal keratosis and cuSCC. This suggests that verrucal keratosis is an early clinical presentation of cuSCC in patients on BRAFi.